{"id":"W2169700609","doi":"10.1200/jco.2012.46.4149","title":"Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Takeda Oncology; Sanofi; Teva Pharmaceutical Industries; Genentech; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Docetaxel; Placebo; Prostate cancer; Internal medicine; Clinical endpoint; Peripheral edema; Adverse effect; Nausea; Hazard ratio; Oncology; Urology; Cancer; Randomized controlled trial; Surgery; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003152197,0.0001542262,0.002753084,0.0003259691,0.00002253338,0.00001198559,0.00008582629,0.00007831486,0.0001041228],"category_scores_gemma":[0.0007071514,0.00007535779,0.0001435016,0.0002798997,0.0002236378,0.0002178391,0.00001477221,0.000578972,0.000001148838],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002736791,"about_ca_system_score_gemma":0.001473293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007514525,"about_ca_topic_score_gemma":0.001586941,"domain_scores_codex":[0.9953536,0.001001955,0.0026058,0.0001770096,0.0006337002,0.0002278749],"domain_scores_gemma":[0.9952708,0.001606284,0.001882571,0.0001204003,0.0009357597,0.000184199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7737049,0.02731655,0.1875297,0.00003296595,0.0009662188,0.0002771661,0.000744932,0.000107149,0.00002854777,0.000006413455,0.00003967753,0.009245807],"study_design_scores_gemma":[0.7675517,0.05361736,0.1766356,0.0001902034,0.0005439121,0.000005478219,0.00101928,0.000285725,0.00001695525,0.0000659518,0.000008252604,0.00005955165],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924314,0.0002030167,0.00001150248,0.001312919,0.0001072981,0.005773655,0.00000366109,0.000002415705,0.0001541112],"genre_scores_gemma":[0.9987964,0.0001720666,0.0003887804,0.00008594815,0.00003376148,0.0003092602,0.000006574836,0.00001285809,0.0001943203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02630081,"threshold_uncertainty_score":0.3073002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06085388927927497,"score_gpt":0.4502794007597806,"score_spread":0.3894255114805056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}